Abrysvo was approved and recommended in 2023 by the Centers for Disease Control (CDC) and the American College of Obstetricians and Gynecologists (ACOG) for use during pregnancy for the prevention of severe RSV disease in young infants.
Immunizing pregnant women against RSV helps protect infants from birth through the most vulnerable first months of their lives.
- RSV is a leading cause of hospitalization among infants ≤ 6months of age
- In infants < 1 year, RSV is responsible for
- ~80,000 annual hospitalizations
- ~132,000 annual emergency room visits
- ~100 annual respiratory deaths

